Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Hanne Blakstad, Janani Moorthy, Karin Andersson, Ingela Raunert, Thomas Henry, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Øyvind Humberset, Per Bergström, Måns Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Rydén, Asgeir S Jakola, Einar O Vik-Mo, Hanne C Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Corina Silvia Rueegg, Inge C Olsen, Rolf J Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand, Petter Brandal
INTRODUCTION: The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and holds promise of reduced long-term side effects. However, the sparing of seemingly non-cancerous tissue is not necessarily positive for isocitrate dehydrogenase ( IDH )-mutated diffuse gliomas grade 2-3, which have a diffuse growth pattern...
March 20, 2023: BMJ Open